Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor that also exhibits sodium channel blocking properties and is indicated for the treatment of Parkinson’s disease. In pharmaceutical development… Read more









![Chemical structure of (S)-2-[3-(2-Fluoro-benzyl)-4-(2-fluoro-benzyloxy)-benzylamino]propanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1000370-28-4-S-2-3-2-Fluoro-benzyl-4-2-fluoro-benzyloxy-benzylaminopropanamide.png&w=3840&q=75)
![Chemical structure of (S)-2-[[3-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1000370-27-3-S-2-3-3-Fluorobenzyl-4-3-fluorobenzyloxybenzylaminopropanamide.png&w=3840&q=75)
![Chemical structure of (S)-2-[[3-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide Methanesulfonate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1000370-30-8-S-2-3-3-Fluorobenzyl-4-3-fluorobenzyloxybenzylaminopropanamide-Methanesulfonate.png&w=3840&q=75)
![Chemical structure of (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1160513-60-9-S-2-4-3-Fluorobenzyloxybenzylaminopropionic-Acid.png&w=3840&q=75)


![Chemical structure of 3-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]benzaldehyde](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1000370-24-0-3-3-Fluorobenzyl-4-3-fluorobenzyloxybenzaldehyde.png&w=3840&q=75)

![Chemical structure of 4-[(3-Fluorobenzyl)oxy]benzoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F405-85-6-4-3-Fluorobenzyloxybenzoic-Acid.png&w=3840&q=75)































Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor that also exhibits sodium channel blocking properties and is indicated for the treatment of Parkinson’s disease. In pharmaceutical development and quality control, laboratories require high-quality reference standards for the parent drug, as well as its related substances, to ensure stringent regulatory compliance. This category includes a comprehensive range of critical compounds, such as synthesis-related impurities, degradation products—including N-nitroso forms and oxidation products—and stereoisomers necessary for impurity profiling. Additionally, stable isotope-labelled standards and specific metabolites are available to support accurate pharmacokinetic investigations and mass spectrometry-based analytical validation. By utilizing these characterized reference materials, researchers can conduct robust method validation, stability studies, and safety assessments in alignment with ICH guidelines, ensuring the consistent quality and therapeutic efficacy of the drug product.